MY129626A - Preparations that potentiate immunogenicity in low immunogenic antigens - Google Patents
Preparations that potentiate immunogenicity in low immunogenic antigensInfo
- Publication number
- MY129626A MY129626A MYPI20015558A MY129626A MY 129626 A MY129626 A MY 129626A MY PI20015558 A MYPI20015558 A MY PI20015558A MY 129626 A MY129626 A MY 129626A
- Authority
- MY
- Malaysia
- Prior art keywords
- compositions
- vaccine
- antigens
- immuno
- lysates
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000005847 immunogenicity Effects 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000006166 lysate Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108010030416 proteoliposomes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
THIS INVENTION DISCLOSES MEANS FOR OBTAINING IMMUNOGENIC PEPTIDES, POLYPEPTIDES, PROTEINS, AND THEIR CORRESPONDING NUCLEIC ACID SEQUENCES, TARGET CELLS WITH VACCINE INTEREST , OR LYSATES THEREOF, WITHOUT MAKING STRUCTURAL CHANGES IN SAID ANTIGENS, THROUGH THEIR ASSOCIATION WITH VERY SMALL SIZE PROTEOLIPOSEMES.THE OBJECT OF THE INVENTION IS TO PROVIDE IMMUNOGENIC COMPOSITIONS CONTAINING PEPTIDES, POLYPEPTIDES, PROTEINS, THEIR CORRESPONDING DNA SEQUENCES, CELLS OR THEIR LYSATES AND VERY SMALL SIZE PROTEOLIPOSOMES (VSSP), WHICH ARE FORMED BY BINDING THE OUTER MEMBRANE PROTEIN COMPLEX (OMPC) OF NEISSERIA MENINGITIDIS WITH GANGLIOSIDES, BY MEANS OF HYDROPHOBIC LINK. ADDITIONALLY, IT IS STATED THAT COMPOSITIONS CAN BE FORMULATED ALONE OR IN THE FORM OF EMULSIONS WITH THE INCOMPLETE FREUND'S ADJUVANT (IFA), AND MAY ALSO BE IYOPHILIZED.THE ESSENCE OF THE INVENTION CONSISTS IN DESCRIBING COMPOSITIONS THAT TRIGGERS IMMUNOGENICIY IN LOW IMMUNOGENIC ANTIGENS, SUCH AS GROWTH FACTOR RECEPTORS, WITHOUT IMPARTING STRUCTURAL CHANGES THEREIN. PARTICULARLY, THIS INVENTION REFERS TO PREPARATION OF IMMUNO-STIMULATING COMPOSITIONS CAPABLE OF GENERATING ANTIGEN-SPECIFIC RESPONSES, EVEN IN IMMUNO-COMPROMISED HOST, SUCH AS THOSE SUFFERING FORM CANCER OR VIRAL OR BACTERIAL CHRONIC INFECTIONS. IN SAID PETIENTS, THE ADMINISTRATION OF THE VACCINE COMPOSITIONS DESCRIBED IN THIS INVENTION HAS LEAD TO THE REESTABLISHMENT OF THE FUNCTIONALITY OF THE IMMUNE SYSTEM.VACCINE COMPOSITIONS OF THIS INVENTION CAN BE USED TO PROTECT OR TREAT INFECTIONS, OR AUTO-IMMUNE DISEASES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20000285A CU23000A1 (en) | 2000-12-06 | 2000-12-06 | VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY |
| CU20010166 | 2001-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY129626A true MY129626A (en) | 2007-04-30 |
Family
ID=47289809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20015558 MY129626A (en) | 2000-12-06 | 2001-12-05 | Preparations that potentiate immunogenicity in low immunogenic antigens |
Country Status (1)
| Country | Link |
|---|---|
| MY (1) | MY129626A (en) |
-
2001
- 2001-12-05 MY MYPI20015558 patent/MY129626A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pedersen et al. | Immunocorrelates of CAF family adjuvants | |
| CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| US6027732A (en) | Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances | |
| EA200300640A1 (en) | PHARMACEUTICAL COMPOSITIONS, STRENGTHENING THE IMMUNOGENICITY OF ANTIGENS WITH WEAK IMMUNOGENESS | |
| TW201803907A (en) | Biofusion proteins as anti-malaria vaccines | |
| WO2005007673A3 (en) | Immunogenic peptides | |
| Zhou et al. | Alum adjuvant and built-in TLR7 agonist synergistically enhance anti-MUC1 immune responses for cancer vaccine | |
| AU2004255393B2 (en) | Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines | |
| US20210023192A1 (en) | Immunogenic composition comprising staphylococcal antigens | |
| RU2003110574A (en) | VECTORS FOR DELIVERY OF MOLECULES TO EXPRESS CD11B CELLS | |
| Křupka et al. | Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP | |
| Fernández et al. | Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine | |
| Gerlich et al. | Functions of hepatitis B surface proteins | |
| WO2019086056A1 (en) | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
| MY129626A (en) | Preparations that potentiate immunogenicity in low immunogenic antigens | |
| Fan et al. | Bioconjugated materials in the development of subunit vaccines | |
| CA2429543C (en) | Method for obtaining antigenic aggregates and the use thereof in formulations | |
| ES2242376T3 (en) | ADMINISTRATION OF IMMUNOGEN PARTICLES THROUGH AGSHB PARTICLES. | |
| WO2003063786A3 (en) | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system | |
| Lövgren-Bengtsson et al. | The ISCOM™ technology | |
| US20220395566A1 (en) | Immunogenic composition | |
| WO2002072015A2 (en) | M cell directed vaccines | |
| Montaner et al. | Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route | |
| Sponaas et al. | Immunization with gp96 from Listeria monocytogenes-infected mice is due to N-formylated listerial peptides | |
| CU23009A1 (en) | PREPARATIONS TO POWER THE IMMUNOGENICITY OF PREPARATIONS TO POWER THE IMMUNOGENICITY OF ANTIGENS LITTLE IMMUNOGENIC ANTIGENS LITTLE IMMUNOGENIC |